Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.

Fecha de publicación: 01/02/2024 Fecha Ahead of Print: 23/01/2024

Autores de IDIVAL

Fernando Rivera Herrero

Autor

Autores ajenos al IDIVAL

Carrato A
Pazo-Cid R
Macarulla T
Gallego J
Jiménez-Fonseca P
Cano MT
Rodriguez-Garrote M
Pericay C
Alés I
Layos L
Graña B
Iranzo V
Gallego I
Garcia-Carbonero R
de Mena IR
Guillén-Ponce C
Aranda E

Unidades

ONCOLOGÍA MÉDICA

Investigador Responsable

Fernando Rivera Herrero

Abstract

Nab-Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab-paclitaxel/gemcitabine followed by modified FOLFOX versus nab-paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia. No significant differences in febrile neutropenia, epistaxis or hemorrhage of grade 3 or higher in either group were reported. Two toxic deaths (2.6%) occurred in the experimental group.

Datos de la publicación

ISSN/ISSNe:: 2766-5526, 2766-5526
Tipo:: Article
Páginas:: 2300144-2300144
DOI:: 10.1056/EVIDoa2300144
PubMed:: 38320486

Documentos

No hay documentos

Métricas

Filiaciones

Pazo-Cid R:: Department of Medical Oncology, Aragon Institute of Biomedical Research, Miguel Servet University Hospital, Zaragoza, Spain
Gallego J:: Department of Medical Oncology, Elche University Hospital, Alicante, Spain
Jiménez-Fonseca P:: Department of Medical Oncology, Asturias Central University Hospital, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
Rivera F:: Instituto de Investigación. Department of Medical Oncology, Marques de Valdecilla University Hospital, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
Cano MT:: Department of Medical Oncology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba University, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Reina Sofia University Hospital, Cordoba, Spain
Pericay C:: Department of Medical Oncology, Sabadell University Hospital, Parc Tauli, Sabadell, Spain
Alés I:: Unidad de Gestión Clínica Intercentros (UGCI) Medical Oncology, University Regional and Virgen Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain
Layos L:: Medical Oncology Department, Catalan Institute of Oncology (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol University Hospital, Badalona, Spain
Graña B:: Department of Medical Oncology, A Coruña University Hospital, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain
Iranzo V:: Department of Medical Oncology, University General Hospital Valencia, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia University, Valencia, Spain
Gallego I:: Department of Medical Oncology, Virgen del Rocio University Hospital, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain
Aranda E:: Department of Medical Oncology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba University, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Reina Sofia University Hospital, Cordoba, Spain